Pharmacy Department, Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou 061000, Hebei, China.
Business Department, Cangzhou Central Blood Bank, No. 1, Yongji West Road, Cangzhou 061000, Hebei, China.
Int Immunopharmacol. 2023 Oct;123:110755. doi: 10.1016/j.intimp.2023.110755. Epub 2023 Aug 5.
This study aimed to evaluate the efficacy of nifedipine controlled-release tablets combined with sacubitril valsartan in diabetic nephropathy (DN) patients with hypertension. One hundred and twelve DN patients with hypertension were enrolled. They were randomly divided into the control group (treated with nifedipine controlled-release tablets combined with valsartan) and the observation group (treated with nifedipine controlled-release tablets combined with sacubitril valsartan). Renal function, endothelial function and inflammatory response were examined. After three-months treatment, the levels of clinical indexes (glycosylated hemoglobin, fasting blood glucose, systolic and diastolic blood pressure), renal function indicators (urinary albumin excretion rate, blood urea nitrogen, serum creatinine and cystatin C), endothelial function indicators (microalbumin, angiotensin II, thrombomodulin and cartilage oligomeric matrix protein) and inflammatory response factors (interleukin-6 and tumor necrosis factor-α) in the observation group were significantly lower than those in the control group. Nifedipine controlled-release tablets combined with sacubitril valsartan could effectively alleviate the progression of DN combined with hypertension.
本研究旨在评估硝苯地平控释片联合沙库巴曲缬沙坦在糖尿病肾病（DN）合并高血压患者中的疗效。纳入 112 例 DN 合并高血压患者，随机分为对照组（硝苯地平控释片联合缬沙坦治疗）和观察组（硝苯地平控释片联合沙库巴曲缬沙坦治疗）。检测肾功能、内皮功能和炎症反应。治疗 3 个月后，观察组临床指标（糖化血红蛋白、空腹血糖、收缩压和舒张压）、肾功能指标（尿白蛋白排泄率、血尿素氮、血清肌酐和胱抑素 C）、内皮功能指标（微白蛋白、血管紧张素 II、血栓调节蛋白和软骨寡聚基质蛋白）和炎症反应因子（白细胞介素-6 和肿瘤坏死因子-α）水平均显著低于对照组。硝苯地平控释片联合沙库巴曲缬沙坦可有效缓解 DN 合并高血压的进展。
